Bifluranol (BX341) has anti-androgenic activity and has shown significant anti-prostatic activity in in vivo studies for the treatment of benign prostatic hyperplasia (BPH).

Bifluranol has been studied for its absorption, distribution, and excretion in mouse, rat, ferret, and dog. Following oral administration, Bifluranol is readily absorbed, but its blood concentrations are low due to hepatic uptake and biliary excretion.
After the intravenous administration of [3H]Bifluranol at doses of 200 μg/kg in rats and 60 μg/kg in ferrets, the blood concentrations of 3H decline rapidly during the first 2 to 3 hours. The decrease is more rapid in females (18 min for rats, 30 min for ferrets) than in males (1.0 h for rats, 1.4 h for ferrets). This initial rapid decline is followed by a much slower decrease (40 h for rats, 20 h for ferrets) to concentrations at 96 hours of less than 15 ng Bifluranol equivalents mL-1 (rat) or 1 ng Bifluranol equivalents mL-1 (ferret)[1].